Date: September15,2021 Your Name:_Xiaofei Li

Manuscript Title:Comprehensive bioinformatics analyses identified Homeobox B9 as a potential prognostic biomarker

and therapeutic target for gastric cancer

Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time	e frame: Since the initial planni	ing of the work	
1	All support for the present	√_None	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
Time	e frame: past 36 months		
2	Grants or contracts from	√None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	√None	
4	Consulting fees	√None	

5	Payment or honoraria for	√ None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	√ None	
	testimony		
	•		
7	Support for attending	√ None	
•	meetings and/or travel	\	
	meetings and, or traver		
8	Patents planned, issued or	_ √None	
	pending		
9	Participation on a Data	√None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	√ None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	√ None	
	Stock of Stock options	<u> </u>	
2	Receipt of equipment,	√ None	
_	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	/ None	
12	financial interests		
	illianciai interests		
DIA	ase summarize the above c	anflict of interest in the fo	lowing hov:
- 16	ase summarize the above t	omnet of interest in the lo	IOWING DUA.
	No conflict of interpolating this wa		
	No conflict of interest in this m	anuscript.	
DIA	ase place an "X" next to the	following statement to in	dicate your agreement:
rie	ase piace air A next to the	e ionowing statement to in	uicate your agreement.
	X I certify that I have answ	vered every question and h	ave not altered the wording of any of the questions or

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time	e frame: Since the initial planni	ing of the work	
1	All support for the present	√_None	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
Time	e frame: past 36 months		
2	Grants or contracts from	√None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	√None	
4	Consulting fees	√None	

5	Payment or honoraria for	√ None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	√ None	
	testimony		
	•		
7	Support for attending	√ None	
•	meetings and/or travel	\	
	meetings and, or traver		
8	Patents planned, issued or	_ √None	
	pending		
9	Participation on a Data	√None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	√ None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	√ None	
	Stock of Stock options	<u> </u>	
2	Receipt of equipment,	√ None	
_	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	/ None	
12	financial interests		
	illianciai interests		
DIA	ase summarize the above c	anflict of interest in the fo	lowing hov:
- 16	ase summarize the above t	omnet of interest in the lo	IOWING DUA.
	No conflict of interpolating this wa		
	No conflict of interest in this m	anuscript.	
DIA	ase place an "X" next to the	following statement to in	dicate your agreement:
rie	ase piace air A next to the	e ionowing statement to in	uicate your agreement.
	X I certify that I have answ	vered every question and h	ave not altered the wording of any of the questions or

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time	e frame: Since the initial planni	ing of the work	
1	All support for the present	√_None	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
Time	e frame: past 36 months		
2	Grants or contracts from	√None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	√None	
4	Consulting fees	√None	

5	Payment or honoraria for	√ None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	√ None	
	testimony		
	•		
7	Support for attending	√ None	
•	meetings and/or travel	\	
	meetings and, or traver		
8	Patents planned, issued or	_ √None	
	pending		
9	Participation on a Data	√None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	√ None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	√ None	
	Stock of Stock options	<u> </u>	
2	Receipt of equipment,	√ None	
_	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	/ None	
12	financial interests		
	illianciai interests		
DIA	ase summarize the above c	anflict of interest in the fo	lowing hov:
- 16	ase summarize the above t	omnet of interest in the lo	IOWING DUA.
	No conflict of interpolation this wa		
	No conflict of interest in this m	anuscript.	
DIA	ase place an "X" next to the	following statement to in	dicate your agreement:
rie	ase piace air A next to the	e ionowing statement to in	uicate your agreement.
	X I certify that I have answ	vered every question and h	ave not altered the wording of any of the questions or

Date: September15,2021 Your Name:_Jiayue Fei

Manuscript Title:Comprehensive bioinformatics analyses identified Homeobox B9 as a potential prognostic biomarker

and therapeutic target for gastric cancer

Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	ing of the work √ _None	
Tim	e frame: past 36 months		
2	Grants or contracts from any entity (if not indicated in item #1 above).	√None	
3	Royalties or licenses	√None	
4	Consulting fees	√None	

5	Payment or honoraria for	√ None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	√ None	
	testimony		
	•		
7	Support for attending	√ None	
•	meetings and/or travel	\	
	meetings and, or traver		
8	Patents planned, issued or	_ √None	
	pending		
9	Participation on a Data	√None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	√ None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	√ None	
	Stock of Stock options	<u> </u>	
2	Receipt of equipment,	√ None	
_	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	/ None	
12	financial interests		
	illianciai interests		
DIA	ase summarize the above c	anflict of interest in the fo	lowing hov:
- 16	ase summarize the above t	omnet of interest in the lo	IOWING DUA.
	No conflict of interpolating this wa		
	No conflict of interest in this m	anuscript.	
DIA	ase place an "X" next to the	following statement to in	dicate your agreement:
rie	ase piace air A next to the	e ionowing statement to in	uicate your agreement.
	X I certify that I have answ	vered every question and h	ave not altered the wording of any of the questions or

Date: September15,2021	
Your Name:_Liaoyuan Song	
Manuscript Title:Comprehensive bioinformatics analyses	identified Homeobox B9 as a potential prognostic biomarke
and therapeutic target for gastric cancer	
Manuscript number (if known):	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time	e frame: Since the initial planni	ing of the work	
1	All support for the present	√_None	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
Time	e frame: past 36 months		
2	Grants or contracts from	√None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	√None	
4	Consulting fees	√None	

testimony 7 Support for attending meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or	
lectures, presentations, speakers bureaus, manuscript writing or educational events 6 Payment for expert testimony 7 Support for attending meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or	
manuscript writing or educational events Payment for expert testimony Support for attending meetings and/or travel Patents planned, issued or pending Participation on a Data Safety Monitoring Board or	
educational events Payment for expert testimony Support for attending meetings and/or travel Patents planned, issued or pending Participation on a Data Safety Monitoring Board or	
Payment for expert testimony Support for attending meetings and/or travel Patents planned, issued or pending Participation on a Data Safety Monitoring Board or	
testimony 7 Support for attending meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or	
testimony 7 Support for attending meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or	
meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or	
meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or	
meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or	
Patents planned, issued or pending Participation on a Data	
pending Participation on a Data Safety Monitoring Board or Safety Monitoring Board or	
pending Participation on a Data Safety Monitoring Board or	
pending Participation on a Data Safety Monitoring Board or	
pending Participation on a Data Safety Monitoring Board or Safety Monitoring Board or	
9 Participation on a Data √None Safety Monitoring Board or	
Safety Monitoring Board or	
Safety Monitoring Board or	
Advisory Board	
10 Leadership or fiduciary role √ None	
in other board, society,	
committee or advocacy	
group, paid or unpaid	
11 Stock or stock options √ None	
2 Receipt of equipment, √_None	
materials, drugs, medical	
writing, gifts or other	
`	
Disease summersing the phase conflict of interest in the fallowing beau	
Please summarize the above conflict of interest in the following box:	
No conflict of interest in this manuscript.	
Please place on "Y" payt to the following statement to indicate your agreement:	
Please place an "X" next to the following statement to indicate your agreement:	
Please place an "X" next to the following statement to indicate your agreement:	
services 13 Other financial or non-financial interests None	

Date: September15,2021 Your Name: Guoyan Sun

Manuscript Title:Comprehensive bioinformatics analyses identified Homeobox B9 as a potential prognostic biomarker

and therapeutic target for gastric cancer

Manuscript number (if known):	
-------------------------------	--

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time	e frame: Since the initial planni	ing of the work	
1	All support for the present	√ _None	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
Time	e frame: past 36 months		
2	Grants or contracts from	√None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	√None	
4	Consulting fees	√None	

testimony 7 Support for attending meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or	
lectures, presentations, speakers bureaus, manuscript writing or educational events 6 Payment for expert testimony 7 Support for attending meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or	
manuscript writing or educational events Payment for expert testimony Support for attending meetings and/or travel Patents planned, issued or pending Participation on a Data Safety Monitoring Board or	
educational events Payment for expert testimony Support for attending meetings and/or travel Patents planned, issued or pending Participation on a Data Safety Monitoring Board or	
Payment for expert testimony Support for attending meetings and/or travel Patents planned, issued or pending Participation on a Data Safety Monitoring Board or	
testimony 7 Support for attending meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or	
testimony 7 Support for attending meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or	
meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or	
meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or	
meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or	
Patents planned, issued or pending Participation on a Data	
pending Participation on a Data Safety Monitoring Board or Safety Monitoring Board or	
pending Participation on a Data Safety Monitoring Board or	
pending Participation on a Data Safety Monitoring Board or	
pending Participation on a Data Safety Monitoring Board or Safety Monitoring Board or	
9 Participation on a Data √None Safety Monitoring Board or	
Safety Monitoring Board or	
Safety Monitoring Board or	
Advisory Board	
10 Leadership or fiduciary role √ None	
in other board, society,	
committee or advocacy	
group, paid or unpaid	
11 Stock or stock options √ None	
2 Receipt of equipment, √_None	
materials, drugs, medical	
writing, gifts or other	
`	
Disease summersing the phase conflict of interest in the fallowing beau	
Please summarize the above conflict of interest in the following box:	
No conflict of interest in this manuscript.	
Please place on "Y" payt to the following statement to indicate your agreement:	
Please place an "X" next to the following statement to indicate your agreement:	
Please place an "X" next to the following statement to indicate your agreement:	
services 13 Other financial or non-financial interests None	

Date: September15,2021
Your Name: _Wei Niu

Manuscript Title:Comprehensive bioinformatics analyses identified Homeobox B9 as a potential prognostic biomarker

and therapeutic target for gastric cancer

Manuscript number (if known):_____

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding,	√_None	
	provision of study materials, medical writing, article		
	processing charges, etc.) No time limit for this item.		
Tim	e frame: past 36 months		
2	Grants or contracts from any entity (if not indicated	√None	
	in item #1 above).		
3	Royalties or licenses	√None	
4	Consulting fees	√None	

testimony 7 Support for attending meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or	
lectures, presentations, speakers bureaus, manuscript writing or educational events 6 Payment for expert testimony 7 Support for attending meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or	
manuscript writing or educational events Payment for expert testimony Support for attending meetings and/or travel Patents planned, issued or pending Participation on a Data Safety Monitoring Board or	
educational events Payment for expert testimony Support for attending meetings and/or travel Patents planned, issued or pending Participation on a Data Safety Monitoring Board or	
Payment for expert testimony Support for attending meetings and/or travel Patents planned, issued or pending Participation on a Data Safety Monitoring Board or	
testimony 7 Support for attending meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or	
testimony 7 Support for attending meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or	
meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or	
meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or	
meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or	
Patents planned, issued or pending Participation on a Data	
pending Participation on a Data Safety Monitoring Board or Safety Monitoring Board or	
pending Participation on a Data Safety Monitoring Board or	
pending Participation on a Data Safety Monitoring Board or	
pending Participation on a Data Safety Monitoring Board or Safety Monitoring Board or	
9 Participation on a Data √None Safety Monitoring Board or	
Safety Monitoring Board or	
Safety Monitoring Board or	
Advisory Board	
10 Leadership or fiduciary role √ None	
in other board, society,	
committee or advocacy	
group, paid or unpaid	
11 Stock or stock options √ None	
2 Receipt of equipment, √_None	
materials, drugs, medical	
writing, gifts or other	
`	
Disease summersing the phase conflict of interest in the fallowing beau	
Please summarize the above conflict of interest in the following box:	
No conflict of interest in this manuscript.	
Please place on "Y" payt to the following statement to indicate your agreement:	
Please place an "X" next to the following statement to indicate your agreement:	
Please place an "X" next to the following statement to indicate your agreement:	
services 13 Other financial or non-financial interests None	

Date: September15,2021
Your Name: Lianyi Guo

Manuscript Title:Comprehensive bioinformatics analyses identified Homeobox B9 as a potential prognostic biomarker

and therapeutic target for gastric cancer

Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	ing of the work √ _None	
Tim	e frame: past 36 months		
2	Grants or contracts from any entity (if not indicated in item #1 above).	√None	
3	Royalties or licenses	√None	
4	Consulting fees	√None	

testimony 7 Support for attending meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or	
lectures, presentations, speakers bureaus, manuscript writing or educational events 6 Payment for expert testimony 7 Support for attending meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or	
manuscript writing or educational events Payment for expert testimony Support for attending meetings and/or travel Patents planned, issued or pending Participation on a Data Safety Monitoring Board or	
educational events Payment for expert testimony Support for attending meetings and/or travel Patents planned, issued or pending Participation on a Data Safety Monitoring Board or	
Payment for expert testimony Support for attending meetings and/or travel Patents planned, issued or pending Participation on a Data Safety Monitoring Board or	
testimony 7 Support for attending meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or	
testimony 7 Support for attending meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or	
meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or	
meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or	
meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or	
Patents planned, issued or pending Participation on a Data	
pending Participation on a Data Safety Monitoring Board or Safety Monitoring Board or	
pending Participation on a Data Safety Monitoring Board or	
pending Participation on a Data Safety Monitoring Board or	
pending Participation on a Data Safety Monitoring Board or Safety Monitoring Board or	
9 Participation on a Data √None Safety Monitoring Board or	
Safety Monitoring Board or	
Safety Monitoring Board or	
Advisory Board	
10 Leadership or fiduciary role √ None	
in other board, society,	
committee or advocacy	
group, paid or unpaid	
11 Stock or stock options √ None	
2 Receipt of equipment, √_None	
materials, drugs, medical	
writing, gifts or other	
`	
Disease summersing the phase conflict of interest in the fallowing beau	
Please summarize the above conflict of interest in the following box:	
No conflict of interest in this manuscript.	
Please place on "Y" payt to the following statement to indicate your agreement:	
Please place an "X" next to the following statement to indicate your agreement:	
Please place an "X" next to the following statement to indicate your agreement:	
services 13 Other financial or non-financial interests None	

and therapeutic target for gastric cancer

Date: September15,2021
Your Name:_Jiwei Wang
Manuscript Title:Comprehensive bioinformatics analyses identified Homeobox B9 as a potential prognostic biomarker

Manuscript number (if known):______

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time	e frame: Since the initial planni	ing of the work	
1	All support for the present	√ _None	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
	e frame: past 36 months		
2	Grants or contracts from		
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses		
4	Consulting fees	√None	

testimony 7 Support for attending meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or	
lectures, presentations, speakers bureaus, manuscript writing or educational events 6 Payment for expert testimony 7 Support for attending meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or	
manuscript writing or educational events Payment for expert testimony Support for attending meetings and/or travel Patents planned, issued or pending Participation on a Data Safety Monitoring Board or	
educational events Payment for expert testimony Support for attending meetings and/or travel Patents planned, issued or pending Participation on a Data Safety Monitoring Board or	
Payment for expert testimony Support for attending meetings and/or travel Patents planned, issued or pending Participation on a Data Safety Monitoring Board or	
testimony 7 Support for attending meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or	
testimony 7 Support for attending meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or	
meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or	
meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or	
meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or	
Patents planned, issued or pending Participation on a Data	
pending Participation on a Data Safety Monitoring Board or Safety Monitoring Board or	
pending Participation on a Data Safety Monitoring Board or	
pending Participation on a Data Safety Monitoring Board or	
pending Participation on a Data Safety Monitoring Board or Safety Monitoring Board or	
9 Participation on a Data √None Safety Monitoring Board or	
Safety Monitoring Board or	
Safety Monitoring Board or	
Advisory Board	
10 Leadership or fiduciary role √ None	
in other board, society,	
committee or advocacy	
group, paid or unpaid	
11 Stock or stock options √ None	
2 Receipt of equipment, √_None	
materials, drugs, medical	
writing, gifts or other	
`	
Disease summersing the phase conflict of interest in the fallowing beau	
Please summarize the above conflict of interest in the following box:	
No conflict of interest in this manuscript.	
Please place on "Y" payt to the following statement to indicate your agreement:	
Please place an "X" next to the following statement to indicate your agreement:	
Please place an "X" next to the following statement to indicate your agreement:	
services 13 Other financial or non-financial interests None	